People carrying a rare gene variant have naturally low body fat, healthier livers and better blood sugar levels

One million people provided the data required to identify a rare variant in the FNIP1 gene associated with lower body fat, improved liver health, and stabilized blood sugar levels. This genetic profile correlates with a reduced risk of diabetes and heart disease, with some observers comparing the biological effect of the mutation to the impact of the drug Ozempic.

Scientific American and Nature report that these findings characterize the variant as a potential driver of favorable metabolic traits. While the New York Post and Medical Xpress focus on the natural leanness observed in carriers, SingularityHub notes the massive scale of the research effort used to isolate the specific genetic marker.

Research now turns toward understanding the underlying mechanisms of how the FNIP1 variant influences metabolic processes. Coverage does not yet specify whether these findings will lead to new therapeutic interventions or specific medical screening protocols for the general population.